Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Cardiomyocyte proliferation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Myocardial function is compromised in several forms of heart disease due to the loss of cardiomyocytes and in part to the limited ability of surviving myocytes to re-enter the cell cycle. The ability to induce cardiomyocyte proliferation will improve myocardial function.
MicroRNA induction of cardiac regeneration
The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Treatment of cardiac diseases with modulators of the hippo pathway
InactiveUS20160361340A1Promote proliferation and hypertrophyExcessive growthCompounds screening/testingOrganic active ingredientsDiseaseHeart repair
The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. Further provided are transgenic animals exhibiting altered expression of the atypical cadherin Fat4 and methods using said transgenic animals, or cells isolated therefrom, for the detection of compounds having therapeutic activity toward cardiac hypertrophy or regeneration. Embodiments of the present invention provide methods and composition for therapeutic intervention in cardiac hypertrophy or heart repair by modulating Fat4 and / or Amotl1 (angiomotin-like1). Treatment may include deleting Yap or administering verteporfm. Embodiments of the present invention define the molecular events linking Fat4 and Amotl1 to cardiac growth, and show that Fat4 is required to restrict cardiomyocyte hypertrophy and cardiomyocyte proliferation and that this is mediated by Amotl1.
Owner:INST PASTEUR +2
Microrna induction of cardiac regeneration
ActiveUS20170096671A1Special deliveryGenetically modified cellsCardiomyocyte proliferationCardiac regeneration
The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Method for proliferating cardiomyocytes using micro-rna
InactiveUS20130005796A1Marked proliferation activityOrganic active ingredientsSugar derivativesCardiac muscleHeart disease
Disclosed are: a method for proliferating cardiomyocytes, wherein a miRNA that promotes the proliferation of cardiomyocytes is used; a vector for the treatment of heart diseases; and a pharmaceutical composition or the like for the treatment of heart diseases. Specifically disclosed are: a method for proliferating cardiomyocytes, which uses a miRNA that has a cardiomyocyte proliferation promoting action; a vector for the treatment of heart diseases, which comprises the miRNA; and a pharmaceutical composition or the like for the treatment of heart diseases, which contains the vector. The miRNA is preferably one selected from the group consisting of miR-148a, miR-148b, miR-152 and miR-373 that are mature miRNAs, precursors of the aforementioned miRNAs, and mutants and analogues of the miRNAs and the precursors.
Owner:DAIICHI SANKYO CO LTD
Modulation of tjp1 expression to regulate regeneration of heart cells
PendingUS20190256846A1Organic active ingredientsPeptide/protein ingredientsHeart muscle cell proliferationNeuregulin
The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject comprising the step of administering to the subject a Tjp1 inhibitor, wherein administration of said Tjp1 inhibitor promotes cardiomyocyte proliferation. The invention further includes use of Tjp1 inhibitor in the manufacture of a medicament for a heart disease, a patch, and a nucleic acid encoding a Tjp1 inhibitor. In a particular embodiment, the Tjp1 inhibitor is a nucleic acid, i.e. an siRNA or shRNA of Tjp1. The invention also includes administration of said Tjp1 inhibitor in combination with Neuregulin-1 (NRG1), Fibroblast growth factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst1) and wherein said inhibitor is delivered in an adeno-associated virus of serotype 9 (AAV 9).
Owner:AGENCY FOR SCI TECH & RES +1
Enhanced cardiomyocyte regeneration
ActiveUS20210187123A1Peptide/protein ingredientsMicroencapsulation basedHeart muscle cell proliferationMessenger RNA
Compositions and methods for promoting adult mammalian cardiomyocytes processes and systems for enhancing cardiomyocyte regeneration are described. The invention relates to locally administering a therapeutic agent containing a modified messenger RNA for expressing a mutated serum response factor polypeptide and a modified messenger RNA for expressing a mutated YAP polypeptide into diseased heart muscle to promote cardiomyocyte proliferation and cardiac regeneration.
Owner:ANIMATUS BIOSCIENCES LLC
Compositions and methods for improving cardiac structure and/or function
ActiveUS20210251938A1Organic active ingredientsCardiovascular disorderHeart muscle cell proliferationSystole
Compositions and methods for improving cardiac structure and / or function in subjects in need thereof. The methods include administering to a subject a succinate dehydrogenase inhibitor in an amount and for a time effective to elicit an improvement in cardiac structure and / or function. The subjects include subjects suffering from cardiac damage, such as damage resulting from myocardial infarction or other cardiac events. Improvements in cardiac function include one or more of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, and a decrease in left ventricle internal diameter systole. Improvements in cardiac structure include one or more of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, and a decrease in myocardial lesion size. Compositions for performing the methods are provided.
Owner:WISCONSIN ALUMNI RES FOUND
Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division
The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction. The invention further relates to screening assays designed to identify compounds that modulate the proliferative activity of cardiomyocytes and the use of such compounds in the treatment of cardiac disorders.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Method of inducing cardiomyocytes proliferation and treating heart diseases
ActiveUS10589132B2Induces proliferation of cardiomyocytesPeptide/protein ingredientsSkeletal/connective tissue cellsHeart Muscle CellCardiac myocyte proliferation
An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
Owner:YEDA RES & DEV CO LTD
Modulation of tjp1 expression to regulate regeneration of heart cells
ActiveCN110167564AOrganic active ingredientsPeptide/protein ingredientsHeart muscle cell proliferationNeuregulin
Owner:AGENCY FOR SCI TECH & RES +1
Method of inducing cardiomyocytes proliferation and treating heart diseases
ActiveUS20180318612A1Induced proliferationInduces proliferation of cardiomyocytesPeptide/protein ingredientsSkeletal/connective tissue cellsCardiac muscleHeart disease
An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
Owner:YEDA RES & DEV CO LTD
A therapeutic gene cocktail for heart regeneration
A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.
Owner:ACAD SINIC
A therapeutic gene cocktail for heart regeneration
New drug use of bml-28-4
ActiveCN112494494BPromote proliferationOrganic active ingredientsSkeletal/connective tissue cellsPharmaceutical drugPharmaceutical medicine
The invention discloses a medicine application of BML-284. The use is the application of BML-284 or a pharmaceutically acceptable salt thereof in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that BML-284 can promote the proliferation of rat cardiomyocytes. Therefore, BML‑284 can be used in related fields such as the preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.
Owner:SYNOGENBIOPHARMACO LTD NANJING CHINA
Use of lysophosphatidic acid, lysophosphatidic acid receptor 3, and lysophosphatidic acid receptor 3 agonists
ActiveCN108379275BOrganic active ingredientsPeptide/protein ingredientsHeart muscle cell proliferationPharmaceutical Substances
The invention discloses application of lysophosphatidic acid, a lysophosphatidic acid receptor 3 and a lysophosphatidic acid receptor 3 agonist and relates to the field of biomedicine. The study findsout that lysophosphatidic acid or the lysophosphatidic acid receptor 3 or the lysophosphatidic acid receptor 3 agonist can promote cardiomyocyte proliferation and inhibit cardiomyocyte apoptosis to repair damaged myocardia, significantly reduce myocardial infarct areas and significantly improve cardiac functions after myocardial infarction, and the effect is obvious. Therefore, lysophosphatidic acid, the lysophosphatidic acid receptor 3 and the lysophosphatidic acid receptor 3 agonist can be used in the field of preparation of medicine, preparations and the like for treating or preventing heart diseases, and new medicine and a new treatment idea are provided for treating or preventing heart diseases such as ischemic heart disease.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Vectors and methods for regenerative therapy
ActiveUS11331377B2Peptide/protein ingredientsGenetic material ingredientsCell Cycle GeneCardiac functioning
Owner:UNIV OF WASHINGTON
New drug uses for baricitinib
ActiveCN112587530BPromote proliferationOrganic active ingredientsSkeletal/connective tissue cellsPharmaceutical drugPharmaceutical medicine
The invention discloses a medicinal use of baricitinib. The use is the application of baricitinib or a pharmaceutically acceptable salt or ester thereof in the preparation of a drug for promoting cardiomyocyte proliferation. The present invention proves through experiments that the baricitinib can promote the proliferation of rat cardiomyocytes. Therefore, baricitinib can be used in related fields such as preparing drugs for promoting cardiomyocyte proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.
Owner:SYNOGENBIOPHARMACO LTD NANJING CHINA
Compositions and methods for the treatment of heart disease
PendingUS20210316015A1Improve ejection fractionHigh outputPeptide/protein ingredientsGenetic material ingredientsCytokinesisCardiac troponins
The disclosure relates to compositions and methods for promoting cardiomyocyte cytokinesis and cardiomyocyte proliferation and for use in cardiac regenerative therapy. Embodiments of the disclosure are particularly useful for promoting cytokinesis in adult cardiomyocytes. In embodiments, the disclosure relates to the expression of human cyclin A2 (CCNA2) under the control of a cardiac Troponin T (cTNT) promoter to promote cytokinesis of adult human cardiomyocytes.
Owner:MT SINAI SCHOOL OF MEDICINE
The new application of phenylephrine hydrochloride
ActiveCN112603914BOrganic active ingredientsSkeletal/connective tissue cellsAdrenergicPharmaceutical drug
Owner:SYNOGENBIOPHARMACO LTD NANJING CHINA
Use of miRNA708, and/or 301 cluster microRNAs in improving cardiac function
ActiveCN108324946BOrganic active ingredientsCardiovascular disorderCardiac functioningCardiac myocyte proliferation
The present invention provides the application of miRNA708 and / or microRNA of cluster 301 in improving heart function. Specifically, microRNAs of miRNA708 and / or 301 clusters can (i) promote cardiomyocyte proliferation; (ii) improve cardiomyocyte anti-hypoxic stress ability; (iii) reduce cardiomyocyte apoptosis and death; (iv) induce myocardial cell proliferation; Proliferation and differentiation of stem cells; and / or (v) protecting cardiomyocytes from hypoxic stimulation.
Owner:SHANGHAI EAST HOSPITAL
Compositions and methods for cardiac regeneration
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Compositions and methods for cardiac regeneration
The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Method for proliferation cardiomyocytes using micro-rna
InactiveUS20140213633A1Marked proliferation activityOrganic active ingredientsSugar derivativesCardiac muscleHeart disease
Owner:DAIICHI SANKYO CO LTD
Method for proliferation cardiomyocytes using micro-rna
InactiveUS20140213634A1Marked proliferation activityOrganic active ingredientsSugar derivativesCardiac muscleHeart disease
Owner:DAIICHI SANKYO CO LTD
New drug use of azd3965
ActiveCN112516147BPromote proliferationPromote cytokinesisOrganic active ingredientsSkeletal/connective tissue cellsPharmaceutical drugPharmaceutical medicine
Owner:SYNOGENBIOPHARMACO LTD NANJING CHINA
Cardiomyocyte proliferation promoting agent and use thereof
PendingUS20210363486A1Facilitated DiffusionPromote efficient proliferationOrganic active ingredientsGenetically modified cellsIDH1Isocitrate Dehydrogenase (NAD+)
By using a drug that activates the cell cycle, including a retinoic acid receptor agonist, a phosphatidylinositol 3-kinase (PI3K) inhibiting agent, or an isocitrate dehydrogenase 1 (IDH1) inhibiting agent, cardiomyocytes can be made to propagate efficiently, and engraftment rate of cardiomyocytes can also be increased at the time of transplantation.
Owner:KYOTO UNIV
Reduction of ALMS1 gene expression or inhibition of altröm protein to induce cardiomyocyte proliferation
InactiveUS9040496B2Inhibit expressionReduce expressionSugar derivativesGenetic material ingredientsCardiac muscleCancer research
The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
InactiveUS20210145890A1Inhibits cardiomyocyte proliferationPeptide/protein ingredientsMuscular disorderHeart Muscle CellCardiac myocyte proliferation
Embodiments of the disclosure include methods and compositions related to the proliferation of cardiomyocytes. In particular embodiments, the proliferation of cardiomyocytes is facilitated upon exposure of the cardiomyocytes to agents that affect the sequestering of Yap by dystrophin glycoprotein complex, such agents including those that inhibit DAG1, Yap, or the interaction thereof.
Owner:BAYLOR COLLEGE OF MEDICINE
A drug for treating acute myocardial infarction
ActiveCN112843083BPromote proliferationPromote generationOrganic active ingredientsGenetic material ingredientsVascular endotheliumBiology
The invention provides a drug for treating acute myocardial infarction, which belongs to the technical field of cardiovascular disease drugs. The present invention proves for the first time that the overexpression of non-coding RNA LOC101928034 can effectively promote the proliferation of cardiomyocytes and the angiogenesis of vascular endothelial cells. Therefore, the overexpression reagent of LOC101928034 can be used to prepare cardiomyocyte proliferation promoters and vascular endothelial cell angiogenesis agent, and then it can be used to prepare the medicine for treating acute myocardial infarction, and provide a new medicine for the treatment of acute myocardial infarction.
Owner:QINGDAO CENT HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com